Department of Lung Cancer, Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Huan-Hu-Xi Road, Ti-Yuan-Bei, He Xi District, Tianjin, 300060, China.
Department of Anesthesiology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
J Cancer Res Clin Oncol. 2019 Jun;145(6):1509-1519. doi: 10.1007/s00432-019-02921-3. Epub 2019 Apr 23.
Maintaining telomeres by recruiting telomerase-to-chromosome ends is essential for cancer cell survival. Inhibiting telomerase recruitment to telomeres represents a novel strategy for telomere-based lung cancer therapy. However, approaches for interrupting telomerase recruitment for cancer therapy still need to be explored.
The telomere-binding protein TPP1 is responsible for recruiting telomerase to telomeres and synthesizing telomeres through the association between the oligosaccharide/oligonucleotide-binding (OB)-fold domain of TPP1 and telomerase reverse transcriptase. We overexpressed the TPP1 OB domain (TPP1-OB) by lentivirus infection in lung cancer cells. Telomere length was examined by Southern blot analysis of terminal restriction fragments. The effects of TPP1-OB on cell proliferation, the cell cycle, apoptosis, chemosensitivity, and tumor growth were evaluated in vitro and in vivo.
TPP1-OB inhibited the recruitment of telomerase to telomeres and shortened telomere length by acting as a dominant-negative mutant of TPP1. TPP1-OB resulted in reduced cell proliferation, G1 cell cycle arrest, and increased cell apoptosis in lung cancer cells. Cell apoptosis occurred mainly through the caspase-3-dependent signaling pathway. TPP1-OB also suppressed anchorage-independent growth and tumor growth in vivo. Moreover, we demonstrated that TPP1-OB enhances the sensitivity of lung cancer cells to the chemotherapeutic drug paclitaxel.
Our results suggest that inhibiting TPP1-mediated telomerase recruitment by expressing the TPP1-OB domain is a potential novel strategy for telomere-targeted lung cancer therapy.
通过将端粒酶招募到染色体末端来维持端粒对于癌细胞的存活至关重要。抑制端粒酶向端粒的招募代表了一种基于端粒的肺癌治疗的新策略。然而,用于中断端粒酶招募以进行癌症治疗的方法仍需要探索。
端粒结合蛋白 TPP1 负责通过 TPP1 的寡糖/寡核苷酸结合(OB)结构域与端粒酶逆转录酶之间的关联将端粒酶招募到端粒并合成端粒。我们通过慢病毒感染在肺癌细胞中过表达 TPP1 OB 结构域(TPP1-OB)。通过末端限制性片段的 Southern blot 分析来检测端粒长度。在体外和体内评估 TPP1-OB 对细胞增殖、细胞周期、细胞凋亡、化学敏感性和肿瘤生长的影响。
TPP1-OB 通过充当 TPP1 的显性负突变体来抑制端粒酶向端粒的募集并缩短端粒长度。TPP1-OB 导致肺癌细胞增殖减少、G1 细胞周期停滞和细胞凋亡增加。细胞凋亡主要通过半胱天冬酶-3 依赖性信号通路发生。TPP1-OB 还抑制了体内的锚定非依赖性生长和肿瘤生长。此外,我们证明 TPP1-OB 增强了肺癌细胞对化疗药物紫杉醇的敏感性。
我们的结果表明,通过表达 TPP1-OB 结构域抑制 TPP1 介导的端粒酶募集是一种潜在的新策略,用于基于端粒的肺癌治疗。